-
On Jun 04, 2025，Akeso announce that the National Medical Products Administration (NMPA) has approved the company’s first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of persistent, recurrent, or metastatic cervical cancer, in combination with platinu...Read more »
-
On May 29, the National Medical Products Administration (NMPA) approved the HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) for marketing. It is indicated as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic non-small ...Read more »
-
On May 21, 2025，InnoCare Pharma announced that the China National Medical Products Administration (NMPA) has granted approval for Minjuvi® (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide, followed by Minjuvi monotherapy, for t...Read more »
-
On May 22, 2025，Allist Pharmaceuticals announced that its innovative drug Airuikai (Glecirasib Citrate Tablets), a KRAS-G12C inhibitor, has been officially approved for market launch by the National Medical Products Administration (NMPA). The approval allows Airuikai to be used for the treatment...Read more »
-
On May 22, 2025, Kelun Bio announced that the application for a new indication of its trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK – 2870) (®) had been accepted by the Center for Drug Evaluation (...Read more »
-
In the Long – standing Battle against Cancer, New Anti – cancer Weapons Emerge Continuously, Bringing New Hope to Patients In the protracted war between humans and cancer, new anti – cancer weapons are emerging one after another, bringing new hope to patients. As a shining new s...Read more »
-
In 2021, a 67 – year – old pancreatic cancer patient created a medical miracle. After experiencing surgery, multiple rounds of chemotherapy, and the failure of TIL therapy, the clinical trial of TCR-T cell therapy she participated in made the lung metastases shrink by 72% within 6 mon...Read more »
-
On May 12, 2025, CARsgen announces preliminary clinical data for CT0596, an allogeneic BCMA-targeted CAR-T developed using the THANK-u Plus™ platform. CT0596 is currently being evaluated in an early exploratory clinical study for relapsed/refractory multiple myeloma (R/R MM) or relapsed/refractor...Read more »
-
On May 9, 2025, Hansoh Pharmaceutical announced that a new indication for Ameile (almonertinib mesylate tablets) has been approved for marketing. The new indication is for the adjuvant treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor re...Read more »
-
On May 1,2025,Hansoh Pharmaceutical announces that the Group’s self-developed B7-H4-targeted antibody-drug conjugate (ADC) HS-20089 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (NMPA) of China, wi...Read more »
-
On April 25, 2025,InnoCare Pharma announced that its new generation pan-TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), which accepted the New Drug Application (NDA) of z...Read more »
-
NMPA Approval of Limertinib, a Third-generation EGFR TKI for the First-line Treatment of Lung Cancer
On April 25, 2025,Innovent Biologics announces that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for limertinib as the first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbo...Read more »
Cooperative medical institution of
Beijing Cancer Hospital